Precision BioSciences Inc. (DTIL) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Precision BioSciences Inc. (NASDAQ: DTIL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $7.06 (-5.11% 1D, market cap $194.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DTIL ranks #800 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DTIL carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $202.2M) and CGEN (Compugen Ltd.) posts a C grade (63/100 RQD, P/E 5.5x, ROIC 85.0%, cap $187.3M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per DTIL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001357874), Precision BioSciences Inc. generated $34.3M in revenue (-50.1% YoY), -$45.7M in net income, and -$65.8M in free cash flow against $154.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 58% of 52W Range • RSI-14 at 55.8 (BULLISH MOMENTUM)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While DTIL currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.87) and Max Pain ($7.41) forces dealer call-delta covering toward $10.10.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Precision BioSciences Inc. (DTIL) dropped -5.11% to $7.06, trading at 58% of its 52-week range ($3.53 – $9.62). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -50.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DTIL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DTIL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Precision BioSciences Inc. (DTIL) ranks #800 by composite RQD confidence (30/100, grade E) and #578 by equity capitalization ($194.9M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with DTIL at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DTIL
ACTIVE
Precision BioSciences Inc. | E | 30/100 | — | — | -35.0% | -5.11% | $194.9M | Benchmark Subject |
| PALI Palisade Bio Inc. | E | 32/100 | — | — | -35.0% | -2.52% | $202.2M | /pali-vs-dtil → |
| CGEN Compugen Ltd. | C | 63/100 | 5.5x | 87.3% | 85.0% | -2.94% | $187.3M | /cgen-vs-dtil → |
| ARTV Artiva Biotherapeutics Inc. | E | 27/100 | — | — | -35.0% | -0.95% | $204.8M | /artv-vs-dtil → |
| PLX Protalix BioTherapeutics Inc. | E | 23/100 | — | 48.8% | -13.0% | -0.77% | $208.7M | /plx-vs-dtil → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precision BioSciences Inc. (DTIL) reported GAAP revenue of $34.3M (-50.1% vs. FY2024 revenue of $68.7M , and -29.7% cumulative change since FY2023) , GAAP net income of -$45.7M, operating cash flow of -$65.8M, and free cash flow of -$65.8M (-12.7% YoY). On the balance sheet, DTIL closed FY2025 with $154.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $34.3M | -$45.7M | -$65.8M | -$65.8M | $154.4M | — |
| FY2024 (FY) | 2024-12-31 | $68.7M | $7.2M | -$58.4M | -$58.4M | $136.4M | — |
| FY2023 (FY) | 2023-12-31 | $48.7M | -$61.3M | -$84.1M | -$84.1M | — | — |
As of 2026-11-03, Precision BioSciences Inc. (NASDAQ: DTIL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $7.06 (-5.11% 1D, market cap $194.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DTIL ranks #800 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DTIL carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $202.2M) and CGEN (Compugen Ltd.) posts a C grade (63/100 RQD, P/E 5.5x, ROIC 85.0%, cap $187.3M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per DTIL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001357874), Precision BioSciences Inc. generated $34.3M in revenue (-50.1% YoY), -$45.7M in net income, and -$65.8M in free cash flow against $154.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DTIL last traded at $7.06 (-5.11% on volume of 108,937 shares), positioning the stock +2.77% above its 50-day simple moving average ($6.87) and +7.79% above its 200-day simple moving average ($6.55). Across its 52-week range of $3.53 to $9.62, DTIL sits at the 58.0% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($6.18 to $7.94).
Why DTIL Stock dropped -5.11% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD rating for DTIL is 24 out of 100, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars break down as follows:
Taken together, the investor implication is that the rating's downside drivers (negative ROIC, zero FCF yield, weak forensic scores, minimal insider conviction) dominate. Any upside thesis would need to rest on factors outside the cash-engine and balance-sheet pillars, and the source data does not establish such a thesis. The rating is educational context, not a recommendation.
Precision BioSciences Inc. (DTIL) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances) (per the profile). The source data does not describe the company's products, customers, or revenue model. Revenue is reported in the SEC financials, but the source data does not break it down by source or customer. Not available in source data for further business detail.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $34.3M | $-52.1M | $-45.7M | N/A | $-65.8M | $110.8M | N/A |
| FY 2024 | $68.7M | $-26.2M | $7.2M | N/A | $-58.4M | $85.9M | N/A |
| FY 2023 | $48.7M | $-43.7M | $-61.3M | N/A | $-84.1M | N/A | N/A |
Per the SEC financials, revenue fell from $68.7M in FY 2024 to $34.3M in FY 2025, and operating income was negative in every reported period. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, Altman Z is 0.2 and Piotroski F is 1/9, both indicating weak forensic health. Per the Roarable RQD rating, Debt/Equity is 0.5; the source data does not provide a debt figure for any period.
Per the recent news and catalysts section, the most significant dated item is a headline stating Precision BioSciences will report third-quarter 2026 financial results on November 3, 2026. Another item announces a late-breaking oral presentation for PBGENE-HBV at AASLD The Liver Meeting 2026. Other items are generic market-data posts. One item reports the stock slipping 6.48% to $5.77 as shares retreat toward $5.48 support; this conflicts with the current price of $7.06 in the market data and should be treated as unverified. All news items are tagged YELLOW with MARKET WIRE impact. The butterfly supply-chain graph reports supply_chain as NONE with no butterfly links and no proprietary signals, so no supply-chain or proprietary signal catalysts are recorded.
Per the Butterfly Supply-Chain Graph, there are no upstream or downstream dependencies, no butterfly links, and no proprietary signals. Sector correlations and 2nd-order bottlenecks cannot be mapped from the source data. An investor should note the Q3 2026 results date as the next known event to watch for changes in the reported financial trend.
Real-time company headlines, analyst actions, and sector developments for Precision BioSciences Inc. (DTIL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.
Welcome to the DTIL (Precision BioSciences Inc.) Roar Pit. Current RQD Composite is 24/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on DTIL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Precision BioSciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on DTIL, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $7.06 (52-wk range $3.53 - $9.62), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).